Integral Molecular was founded to further membrane proteins research conducted at the University of Pennsylvania 1997-2000 that resulted in manuscripts published in the journals Science, PNAS, and Journal of Virology. Working with pharmaceutical, biotechnology, and academic customers and collaborators since its founding, Integral's has designed products to be used throughout the drug discovery process, primarily in the identification and optimization of chemical compounds and in the development of antibodies against integral membrane proteins. With a pipeline of therapeutic antibodies for membrane protein targets, including GPCRs, ion channels, and transporters, the company offers Lipoparticles, a technology that facilitates the discovery of drugs against integral membrane proteins. Its products are used throughout the drug discovery process, focusing on the identification and optimization of chemical compounds and in the development of antibodies against integral membrane proteins.
